Cephalon Submits Fentora sNDA For Chronic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Application includes strengthened risk management plan to ensure appropriate patient use and dosing, a critical concern after deaths were reported following unapproved uses.
You may also be interested in...
Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.
Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.
European Medicines Agency’s CHMP Rejects Celgene’s Revlimid In Myelodysplastic Syndromes
Agency reiterates negative opinion on Wyeth's Mylotarg for acute myeloid leukemia.